Holen Sie sich die Stockscreener-App
112.00
0.35%
0.39
Handel nachbörslich:
112.00
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RVTY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$111.61
Offen:
$112.43
24-Stunden-Volumen:
702.76K
Relative Volume:
0.86
Marktkapitalisierung:
$13.63B
Einnahmen:
$2.72B
Nettoeinkommen (Verlust:
$254.30M
KGV:
18.84
EPS:
5.9463
Netto-Cashflow:
$564.37M
1W Leistung:
-0.44%
1M Leistung:
-4.03%
6M Leistung:
+9.79%
1J Leistung:
+1.42%
1-Tages-Spanne:
$111.36
$113.61
1-Wochen-Bereich:
$109.39
$113.61
52-Wochen-Spanne:
$97.31
$129.50
Revvity Inc Stock (RVTY) Company Profile
Firmenname
Revvity Inc
Sektor
Branche
Telefon
781-663-6900
Adresse
77 4TH AVENUE, WALTHAM
Vergleichen Sie RVTY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
112.00 | 13.63B | 2.72B | 254.30M | 564.37M | 2.0665 |
|
TMO
Thermo Fisher Scientific Inc
|
522.57 | 199.88B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
229.81 | 165.99B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
133.43 | 38.11B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
195.12 | 35.41B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
408.85 | 33.48B | 3.84B | 866.24M | 792.60M | 10.37 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-07-08 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-23 | Fortgesetzt | Goldman | Buy |
Alle ansehen
Revvity Inc Aktie (RVTY) Neueste Nachrichten
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now - MSN
Revvity Inc. stock outperforms competitors despite losses on the day - MarketWatch
Revvity (FRA:PKN) Float Percentage Of Total Shares Outstanding : 75.15% (As of Dec. 30, 2024) - GuruFocus.com
Revvity Inc. stock underperforms Friday when compared to competitors - MarketWatch
(RVTY) Proactive Strategies - Stock Traders Daily
Is Revvity Stock Underperforming the S&P 500? - MSN
Is Revvity Stock Underperforming The S&P 500? - Barchart
Revvity Inc. stock rises Tuesday, still underperforms market - MarketWatch
Revvity, Inc. (NYSE:RVTY) Receives $132.47 Consensus Target Price from Brokerages - MarketBeat
China Neurogenomics Market Research 2024-2031, Profiles of Illumina, Thermo Fisher Scientific, F. Hoffmann-La Roche, MGI Tech, Agilent, Revvity, Qiagen, Pacific Biosciences, Danaher, Oxford NanoporeResearchAndMarkets.com - WICZ
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
How To YieldBoost Revvity To 12.8% Using Options - Nasdaq
Why Revvity, Inc. (NYSE:RVTY) Could Be Worth Watching - Simply Wall St
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Scale Biosciences and Revvity’s BioLegend launch high parameter protein profiling of single cells - SelectScience
Revvity Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Revvity CEO to Present Strategic Vision at J.P. Morgan Healthcare Conference 2025 - StockTitan
Jane Street Group LLC Sells 164,156 Shares of Revvity, Inc. (NYSE:RVTY) - MarketBeat
Trend Tracker for (RVTY) - Stock Traders Daily
Revvity Inc. stock underperforms Monday when compared to competitors - MarketWatch
Safe Biopharma: Revvity’s Recurring Revenues And Diagnostics (NYSE:RVTY) - Seeking Alpha
Tidal Investments LLC Buys 50,666 Shares of Revvity, Inc. (NYSE:RVTY) - MarketBeat
Revvity, Inc. (NYSE:RVTY) Shares Purchased by Geode Capital Management LLC - MarketBeat
Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst - Benzinga
Revvity (NYSE:RVTY) Raised to Buy at Bank of America - MarketBeat
Revvity Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Fmr LLC Purchases 45,040 Shares of Revvity, Inc. (NYSE:RVTY) - MarketBeat
Can Revvity, Inc. (NYSE:RVTY) Performance Keep Up Given Its Mixed Bag Of Fundamentals? - Yahoo Finance
State Street Corp Acquires 17,832 Shares of Revvity, Inc. (NYSE:RVTY) - MarketBeat
Revvity, Inc. (NYSE:RVTY) Shares Sold by First National Bank of Omaha - MarketBeat
Quantinno Capital Management LP Has $5.58 Million Stock Holdings in Revvity, Inc. (NYSE:RVTY) - MarketBeat
Trading (RVTY) With Integrated Risk Controls - Stock Traders Daily
Why Is Revvity (RVTY) Down 8.7% Since Last Earnings Report? - MSN
Cinctive Capital Management LP Makes New $2.31 Million Investment in Revvity, Inc. (NYSE:RVTY) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 48,700 Shares of Revvity, Inc. (NYSE:RVTY) - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Raises Stake in Revvity, Inc. (NYSE:RVTY) - MarketBeat
Verition Fund Management LLC Has $8.41 Million Stake in Revvity, Inc. (NYSE:RVTY) - MarketBeat
Timber Creek Capital Management LLC Acquires 4,336 Shares of Revvity, Inc. (NYSE:RVTY) - MarketBeat
Bank of Montreal Can Trims Stock Position in Revvity, Inc. (NYSE:RVTY) - MarketBeat
BNP Paribas Financial Markets Trims Stake in Revvity, Inc. (NYSE:RVTY) - MarketBeat
RVTY (Revvity) EV-to-Revenue : 5.96 (As of Nov. 29, 2024) - GuruFocus.com
Gene Editing Market Forecast Report 2024, with Profiles of Merck, GenScript, Revvity, Lonza, Precision BioSciences, Cellectis, AMSBIO, Synthego, Takara Bio, Bio-Techne, Reprocell and More - Yahoo Finance
Revvity, Inc. (NYSE:RVTY) Shares Sold by Citigroup Inc. - MarketBeat
Revvity broadens relationship with Genomics England to advance genomics in the UK - SelectScience
Zacks Research Issues Positive Outlook for Revvity Earnings - MarketBeat
Finanzdaten der Revvity Inc-Aktie (RVTY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.49%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):